Equities research analysts at StockNews.com started coverage on shares of Minerva Neurosciences (NASDAQ:NERV – Get Free Report) in a research note issued on Friday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Separately, HC Wainwright cut their target price on shares of Minerva Neurosciences from $7.00 to $5.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 7th.
Get Our Latest Analysis on Minerva Neurosciences
Minerva Neurosciences Stock Up 0.7 %
Minerva Neurosciences (NASDAQ:NERV – Get Free Report) last issued its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported ($1.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.97) by ($0.12). On average, equities analysts expect that Minerva Neurosciences will post -1.89 earnings per share for the current year.
Minerva Neurosciences Company Profile
Minerva Neurosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of product candidates for the treatment of central nervous system diseases. Its lead product candidate is roluperidone (MIN-101) for the treatment of negative symptoms in patients with schizophrenia, currently submitted an New Drug Application (NDA); and MIN-301, a soluble recombinant form of the neuregulin-1b1 protein for the treatment of Parkinson's disease and other neurodegenerative disorders.
See Also
- Five stocks we like better than Minerva Neurosciences
- Russell 2000 Index, How Investors Use it For Profitable Trading
- Does A&F’s Q2 Earnings Win Point to a Strong Holiday Season?
- Health Care Stocks Explained: Why You Might Want to Invest
- Best Buy Stock Flashes Bullish Signal, Challenges Remain
- How to Effectively Use the MarketBeat Ratings Screener
- Affirm Shows Buy-Now-Pay-Later Is Here to Stay in Latest Results
Receive News & Ratings for Minerva Neurosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Minerva Neurosciences and related companies with MarketBeat.com's FREE daily email newsletter.